Drugs / LMP2-SPECIFIC CYTOTOXIC T-LYMPHOCYTES
LMP2-SPECIFIC CYTOTOXIC T-LYMPHOCYTES
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00383097 | Sep 2006 → Feb 2010 | Hodgkins lymphoma, non-Hodgkin lymphoma | Baylor College of Medicine | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LMP2-SPECIFIC CYTOTOXIC T-LYMPHOCYTES | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00383097 ↗ |
| Action | Deplete | “T cells, that have been trained to kill EBV infected cells” NCT00383097 ↗ |
| Modality | Cell therapy | “special immune system cells called LMP1- and LMP2-specific cytotoxic T lymphocytes (LMP1- and LMP2-CTLs), a new experimental therapy” NCT00383097 ↗ |
| Route | Intravenous | “LMP1- and LMP2-specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line” NCT00383097 ↗ |